In view of the fact that TP53, KRAS, and BRAF are commonly mutated genes in CRC (Russo et al., 2005; Sinicrope et al., 2015; Guo et al., 2019), we analyzed the performance of the IGBRS among patients with different TP53, KRAS, and BRAF mutation statuses. This evidence concerns the gene TP53 and colorectal carcinoma.